This manuscript provides a step-by-step procedure for the derivation and maintenance of human keratinocytes from plucked hair and subsequent generation of integration-free human induced pluripotent stem cells (hiPSCs) by episomal vectors.
Recent advances in reprogramming allow us to turn somatic cells into human induced pluripotent stem cells (hiPSCs). Disease modeling using patient-specific hiPSCs allows the study of the underlying mechanism for pathogenesis, also providing a platform for the development of in vitro drug screening and gene therapy to improve treatment options. The promising potential of hiPSCs for regenerative medicine is also evident from the increasing number of publications (>7000) on iPSCs in recent years. Various cell types from distinct lineages have been successfully used for hiPSC generation, including skin fibroblasts, hematopoietic cells and epidermal keratinocytes. While skin biopsies and blood collection are routinely performed in many labs as a source of somatic cells for the generation of hiPSCs, the collection and subsequent derivation of hair keratinocytes are less commonly used. Hair-derived keratinocytes represent a non-invasive approach to obtain cell samples from patients. Here we outline a simple non-invasive method for the derivation of keratinocytes from plucked hair. We also provide instructions for maintenance of keratinocytes and subsequent reprogramming to generate integration-free hiPSC using episomal vectors.
The discovery of human induced pluripotent stem cells (hiPSCs) has revolutionized the field of regenerative medicine, providing a feasible method for generation of patient-specific stem cells 1-3. hiPSCs have been successfully generated from various somatic cell types, including fibroblasts 4,5, hematopoietic cells 6,7, renal epithelial cells from urine 8 and keratinocytes 9,10. To date, skin fibroblasts and hematopoietic cells represent the most commonly used cell sources for generating patient-specific iPSCs. Arguably, this is due to the fact that skin biopsies and blood collection are routine medical procedures and large biobanks of patient blood or skin samples have been established in many countries.
In contrast to blood cells and skin fibroblast which require invasive extraction methods, keratinocytes represent an easily accessible cell type for hiPSC generation. Keratinocytes are keratin-rich epithelial cells that form the exterior epidermal barrier of the skin and are also found in nails and hair 11. In particular, keratinocytes can be found on the outer root sheath (ORS) of hair follicles, an external cellular layer that covered the hair shaft together with the inner root sheath (IRS) cells (12, Figure 1). As hair collection is a simple procedure that does not require the assistance of medical personnel, it provides an opportunity for patients to collect and send their own hair samples to laboratories, which would greatly facilitate the collection of patient samples for hiPSC generation. Epidermal keratinocytes also have a higher reprogramming efficiency and faster reprogramming kinetics compared to fibroblasts, adding to the advantages of using keratinocytes as the starting cells for hiPSC generation 9,13. Furthermore, hiPSCs can also be generated using other cell populations within the hair follicle, including the dermal papilla cells located at the base of the hair follicle 14,15.
Previous reports of iPSC generation using hair-derived cells often utilize retroviral or lentiviral-based reprogramming methods 9,14,15. However, these viral methods introduce undesirable genomic integration of foreign transgenes during reprogramming. In comparison, the use of episomal vectors represents a feasible, non-viral reprogramming method to generate integration-free iPSCs 4. We have previously developed a simple, cost-effective and non-viral method to efficiently reprogram keratinocyte into hiPSCs using episomal vectors 13. Here we provide a detailed protocol for the generation of keratinocyte-derived hiPSCs, including the derivation of keratinocytes from plucked hair, expansion and maintenance of the keratinocytes and subsequent reprogramming to generate hiPSCs.
The collection of human hair sample from individuals requires ethical approval by the human research ethics committee in the host institutions and should be done in compliance with the institutional guidelines.
1. Isolation of Keratinocytes from Plucked Hair
2. Maintenance and Passaging of Keratinocytes
3. Generation of hiPSCs from Keratinocytes Using Episomal Vectors
The hair goes through 3 different phases of growth cycle: anagen (the growth phase), catagen (the regression phase) and telogen (the rest phase) 20,21. The anagen hair follicle contains multiple layers of epithelium; these layers include the ORS, IRS and the hair shaft (Figure 1). Anagen hair eventually undergoes transition to the catagen phase, which is marked by apoptosis of the ORS and termination of hair shaft differentiation. Finally, catagen hair transition to the telogen phase, where apoptosis ceases and the telogen follicle becomes quiescent with a characteristic telogen bulge 20,21.
Figure 1 illustrates the morphology of a telogen hair and an anagen hair. We typically utilize anagen hair for keratinocyte derivation. Following this protocol, keratinocyte outgrowths can be observed as early as 3 days after hair attachment (Figure 2A) and will continue to proliferate (Figure 2B). In our experience, some anagen hairs may fail to attach or fail to observe keratinocyte outgrowth; thus collect at least 5 – 10 anagen hairs from each individual to ensure successful keratinocyte isolation. Subsequently, the keratinocytes can be passaged onto a new plate and maintained for multiple passages (Figure 2C). It is important to note that there is better growth of keratinocytes on a Coating Matrix with Keratinocyte medium as described in section 2, compared to Matrigel with KSR medium.
Following expansion, the keratinocytes can be reprogrammed to generate hiPSCs as described in section 3. Figure 3A shows a typical keratinocyte-derived hiPSC colony after 32 days of reprogramming. It is common to observe some differentiation at the center of the hiPSC colony. Once manually picked, the derived hiPSCs typically display high nucleus to cytoplasmic ratio and a defined colony boundary (Figure 3B). Established cell lines of hiPSCs can then be characterized for pluripotency as described previously 13,19, such as the expression of pluripotent markers OCT4, NANOG and TRA-160 (Figure 3C-E).
Figure 1. Representative images of plucked hairs at different growth phases. (A) Diagram illustrating hairs in the anagen or telogen phase. Phase contrast images showing a plucked hair in (B) telogen phase and (C) anagen phase. HS = hair shaft; IRS = Inner Root Sheath; ORS = Outer Root Sheath. Scale bar = 100 µm. Please click here to view a larger version of this figure.
Figure 2. Representative images of hair-derived keratinocytes. Phase contrast images of a plucked hair plated down for (A) 3 days and (B) 10 days. White arrows mark the outgrowth of keratinocyte from a plucked hair. (C) Phase contrast image of Day 3 keratinocyte culture with a typical cobblestone morphology after passaging. Scale bar = 100 µm. Please click here to view a larger version of this figure.
Figure 3. Representative images of keratinocyte-derived hiPSCs. (A) Phase contrast image of a Day 32 reprogramming culture showing a keratinocyte-derived hiPSC colony. (B) Manually selected keratinocyte-derived hiPSCs with morphology similar to hESCs. Immunostaining of hiPSCs with pluripotent markers (C) NANOG and (D) OCT4 and (E) TRA-160 in keratinocyte-derived hiPSCs. Scale bar = 100 µm. Please click here to view a larger version of this figure.
Generation of patient-specific hiPSCs offers a unique approach for studying pathogenesis in the diseased cell types in vitro, and also provides a platform for drug screening to identify novel molecules that can rescue the disease phenotypes. This disease modeling approach using hiPSCs has yielded promising results for a variety of diseases, including Long QT syndrome, Huntington’s disease, Parkinson’s disease and amyotrophic lateral sclerosis 22. Several initiatives are already underway to establish large-scale libraries of patient-specific hiPSCs, including consortiums in USA, Europe, Australia, China, South Korea and Japan 23,24.
Here a protocol to establish hiPSCs from hair-derived keratinocytes is described, which has the potential to facilitate and fast-track the establishment of large-scale libraries of disease-specific hiPSCs. This protocol offers two advantages: Firstly, the episomal system utilized in this protocol generates integration-free hiPSCs using a cocktail of six reprogramming factors (OCT4, SOX2, KLF4, L-MYC, LIN28, shRNA for p53) at relatively high efficiency 4. Compared to retroviral or lentiviral-mediated reprogramming methods, the use of episomal vector avoids undesirable genomic integration of foreign transgenes during reprogramming., Therefore, many initiatives favor the use of integration-free reprogramming methods for establishment of large-scale hiPSC libraries, such as episomal vectors, Sendai virus or mRNA, over integrative reprogramming methods 23.
Secondly, hair is easily accessible and can be harvested by the patients themselves without the use of invasive procedures or the attendance of medical staffs. This provides a unique opportunity for patients from different regions to collect and mail in their own hair samples to the laboratory for keratinocyte derivation and subsequent reprogramming. In support of the feasibility of this strategy, our unpublished data indicate that keratinocytes can be successfully isolated from plucked hair that was stored at 4 °C for up to 10 days.
The methodology described here will allow the derivation of keratinocyte from plucked hair. While keratinocytes can be derived from just a single hair, our recommendation is to collect at least 5 anagen hairs for keratinocyte derivation. One limitation of this protocol is that some hairs may not attach well and the keratinocytes may fail to grow. Thicker hair tends to attach better, while fine hair requires reduced amount of culture medium during plating to avoid floating and enhance attachment. Once keratinocytes are derived, it is advisable to expand and freeze down stocks using standard slow-freezing cryopreservation methods 16. Subsequent reprogramming of keratinocytes can be performed following steps described in this protocol. It is important to note that the proliferation rate of the starting cells may affect the reprogramming efficiency, with decreased reprogramming efficiency observed in late passages as cells reach cellular senescence 25-27. In this regard, use keratinocytes no later than passage 6 for reprogramming experiments. In addition, reprogramming efficiencies may vary between different individual’s keratinocytes.
Recent studies suggest widespread genetic mosaicism in multiple types of somatic tissues 28, with ~30% of skin fibroblasts reported to have somatic CNVs in the genome 29. These CNVs may be caused by errors in DNA replication, DNA repair or transposon mobilization. It is also possible that prolonged UV exposure to the skin can cause additional CNVs in epidermal cells including fibroblasts and keratinocytes, but the extent of this is not well understood. As CNVs in keratinocytes will be carried over during the reprogramming process, it is important to perform routine karyotyping or CNV analysis to ensure that the established hiPSCs maintain genomic stability. In summary, here we described procedures for generation of hiPSCs from hair-derived keratinocytes, which could be used for disease modeling and regenerative medicine.
The authors have nothing to disclose.
The authors wish to thank Harene Ranjithakumaran and Stacey Jackson for technical support. This work was supported in part by grants from the National Health and Medical Research Council (R.C.B. Wong, A. Pébay), the University of Melbourne (R.C.B. Wong), Retina Australia (R.C.B. Wong, S.S.C. Hung, A. Pébay) and the Ophthalmic Research Institute of Australia (R.C.B. Wong, S.S.C. Hung, A. Pébay); Australian Research Council Future Fellowship (A. Pébay, FT140100047), Cranbourne Foundation Fellowship (R.C.B. Wong); intramural funding from the National Institutes for Health (R.C.B. Wong, S.S.C. Hung) and operational infrastructure support from the Victorian Government.
Antibiotic Mix: | |||
250 ng/ml Antimycotic amphotericin B | Sigma | A2942-20ml | Antibiotic mix is made up in PBS. |
1X Penicillin/Streptomycin | Invitrogen | 15140-122 | |
PBS (-) | Invitrogen | 14190-144 | |
Knockout Serum Replacement (KSR) medium: | KSR medium is filtered using Stericup (Millipore, #SCGPU05RE) before use. bFGF is added fresh to the media before use. | ||
20% knockout serum replacement (KSR) | Invitrogen | 10828-028 | |
DMEM/F12 with glutamax | Invitrogen | 10565-042 | |
1× MEM non-essential amino acid | Invitrogen | 11140-050 | |
0.5× Penicillin/Streptomycin | Invitrogen | 15140-122 | |
0.1 mM β-mercaptoethanol | Invitrogen | 21985 | |
bFGF (10 ng/ml, added fresh) | Millipore | GF003 | |
Keratinocyte medium: | |||
EpiLife with 60 µM Calcium | Invitrogen | M-EPI-500-CA | |
1× Human keratinocyte growth supplement (HKGS) | Invitrogen | S-001-5 | |
Fetal Bovine Serum (FBS) medium: | FBS medium is filtered using Stericup (Millipore, #SCGPU05RE) before use. | ||
10% fetal bovine serum (FBS) | Invitrogen | 26140079 | |
DMEM | Invitrogen | 11995-073 | |
0.5× Penicillin/Streptomycin | Invitrogen | 15140-122 | |
2 mM L-glutamine | Invitrogen | 25030 | |
0.25% trypsin-EDTA | Invitrogen | 25200-056 | |
Extracellular Matrix (ECM): | |||
Matrigel | Corning | 354234 | Aliquot Matrigel stock and store in -80°C following manufacturer’s instructions. Stock concentration of Matrigel varies slightly from batch to batch (~9mg/ml). We recommend to use 200µl matrigel for coating a 12-well plate (~150µg/well). |
Coating Matrix Kit | Invitrogen | R-011-K | |
Plasmids: | Note that pCXLE-eGFP is only used for monitoring transfection efficiency and is not required for reprogramming. | ||
- pCXLE-eGFP | Addgene | 27082 | |
- pCXLE-hOct3/4-shP53F | Addgene | 27077 | |
- pCXLE-hSK | Addgene | 27078 | |
- pCXLE-hUL | Addgene | 27080 | |
Transfection reagent Fugene HD | Promega | E231B | |
Gelatin (from porcine skin) | Sigma | G1890 | Make up 0.1% gelatin in distilled water. Autoclave before use. |
Reduced Serum medium: OPTI-MEM | Invitrogen | 31985062 | |
Accutase | Sigma | A6964-100ml | |
Mouse embryonic fibroblast (MEF) feeder | MEF can be inactivated by mitomycin C treatment or irradiation as described previously 16. | ||
26G needle | Terumo | NN2613R | |
6-well plate (tissue culture treated) | BD Biosciences | 353046 | |
12-well plate (tissue culture treated) | BD Biosciences | 353043 | |
10 cm dish (tissue culture treated) | BD Biosciences | 353003 | |
Dispase | Invitrogen | 17105-041 | Use at 10mg/ml |
Collagenase IV | Invitrogen | 17104-019 | Use at 1mg/ml |
TRA-160 antibody | Millipore | MAB4360 | Use at 5µg/ml |
OCT4 antibody | Santa Cruz | SC-5279 | Use at 5µg/ml |
NANOG antibody | R&D Systems | AF1997 | Use at 10µg/ml |
MycoAlert Detection kit | Lonza | LT07-418 |